Immunoassay heterogeneity le litlamorao tsa SARS-CoV-2 serosurveillance

Serosurveillance e sebetsana le ho hakanya ho ata ha li-antibodies sechabeng khahlanong le pathogen e itseng.E thusa ho lekanya ts'ireletso ea ts'oaetso ea ts'oaetso ea batho kamora tšoaetso kapa ente 'me e na le ts'ebeliso ea epidemiological ho lekanya likotsi tsa phetiso le maemo a ts'ireletso ea baahi.Ho seoa sa hona joale sa lefu la coronavirus la 2019 (COVID-19), serosurvey e phethile karolo ea bohlokoa ho lekola boemo ba ts'oaetso e matla ea lefu le matla la ho hema coronavirus 2 (SARS-CoV-2) lichabeng tse fapaneng.E boetse e thusitse ho theha matšoao a epidemiologic, mohlala, the infection fatality ratio (IFR).

Qetellong ea 2020, li-serosurvey tse 400 li ne li phatlalalitsoe.Lithuto tsena li ne li ipapisitse le mefuta e fapaneng ea li-immunoassays tse neng li etselitsoe ho sekaseka li-antibodies khahlano le SARS-CoV-2, haholo-holo li shebile tsohle kapa karolo ea liprotheine tsa spike (S) le nucleocapsid (N) tsa SARS-CoV-2.Boemong ba hona joale ba seoa sa COVID-19, maqhubu a seoa a latellanang a ntse a etsahala libakeng tse fapaneng tsa lefats'e, a tšoaetsa batho ba bangata ka nako e itseng.Ketsahalo ena e phephelitse SARS-CoV-2 serosurveillance ka lebaka la tikoloho e ntseng e eketseha e fapaneng ea immunology.

Bo-rasaense ba hlokometse hore maemo a anti-SARS-CoV-2 a na le tšekamelo ea ho bola kamora nako ea pholiso.Ketsahalo e joalo e eketsa menyetla ea liphello tse mpe ka li-immunoassays.Maemo ana a fosahetseng a ka nyenyefatsa ho teba ha sekhahla sa 'nete sa tšoaetso ntle le haeba a lemohuoa le ho lokisoa kapele.Ntle le moo, li-antibody kinetics tsa kamora ts'oaetso li hlaha ka tsela e fapaneng ho latela botebo ba ts'oaetso - ts'oaetso e matla le ho feta ea COVID-19 e batla ho kenyelletsa keketseho e kholo ea boemo ba li-antibodies ha bo bapisoa le ts'oaetso e bobebe kapa ea asymptomatic.

Lithuto tse 'maloa li bontšitse li-antibody kinetics likhoeli tse tšeletseng ka mor'a tšoaetso.Lithuto tsena li fumane hore boholo ba batho metseng e tšoaelitsoeng ke SARS-CoV-2 ba bonts'a ts'oaetso e bobebe kapa ea asymptomatic.Bafuputsi ba lumela hore ho bohlokoa ho lekanya phetoho maemong a li-antibodies, ho sebelisoa litlhahlobo tse fumanehang tsa immunoassay, ho pholletsa le bongata bo boholo ba tšoaetso.Lilemo le tsona li ne li nkoa e le ntlha ea bohlokoa lithutong tsena.

Phuputsong ea morao tjena, bo-ramahlale ba lekanyelitse maemo a anti-SARS-CoV-2 antibody ho fihlela likhoeling tse 9 kamora ts'oaetso, mme ba phatlalalitse liphuputso tsa bona homedRxiv* seva sa preprint.Phuputsong ea hajoale, sehlopha sa batho ba nang le seropositive se ile sa thaothoa ka li-serosurveys tse entsoeng Geneva, Switzerland.Bafuputsi ba sebelisitse li-immunoassay tse tharo tse fapaneng, e leng, semiquantitative anti-S1 ELISA detecting IgG (e bitsoang EI), quantitative Elecsys anti-RBD (e bitsoang, Roche-S) le semiquantitative Elecsys anti-N (e bitsoang Roche- N).Patlisiso ea hajoale e fana ka temohisiso ea bohlokoa lithutong tsa serologic tse thehiloeng ho baahi mme e bonts'a ho rarahana ha tikoloho ea 'mele ea ho itšireletsa mafung ka lebaka la motsoako oa ts'oaetso ea morao-rao ea COVID-19, hammoho le ente.

Boithuto bo ntseng bo nahanoa bo tlalehile hore batho ba tšoaelitsoeng ke COVID-19 ba nang le matšoao a bobebe kapa ba neng ba le asymptomatic, ba senotse boteng ba li-antibodies.Li-antibodies tsena li ne li shebane le liprotheine tsa nucleocapsid (N) kapa spike (S) tsa SARS-CoV-2 mme li fumanoe li phehella bonyane likhoeli tse 8 kamora ts'oaetso.Leha ho le joalo, ho fumanoa ha bona ho itšetlehile haholo ka khetho ea immunoassay.Bafuputsi ba fumane hore litekanyo tsa pele tsa li-antibodies, tse nkiloeng ho barupeluoa nakong ea likhoeli tse 'ne le halofo tsa COVID-19, li ne li tšoana ho mefuta eohle e meraro ea li-immunoassay tse sebelisitsoeng thutong ena.Leha ho le joalo, ka mor'a likhoeli tse 'nè tsa pele, le likhoeli tse robeli ka mor'a tšoaetso, liphello li ile tsa fapana ho ea ka liteko.

Patlisiso ena e senotse hore tabeng ea tlhahlobo ea EI IgG, motho a le mong ho ba bane o ne a e-na le sero-reverted.Leha ho le joalo, bakeng sa li-immunoassays tse ling, joalo ka liteko tsa Roche anti-N le anti-RBD kakaretso ea Ig, ke tse seng kae feela kapa tse se nang sero-reversions tse ileng tsa fumanoa bakeng sa sampole e tšoanang.Le barupeluoa ba nang le ts'oaetso e bobebe, bao pele ho neng ho nahanoa hore ba na le likarabo tse fokolang tsa 'mele oa ho itšireletsa mafung, ba bontšitse kutlo ha ba ntse ba sebelisa liteko tsa anti-RBD le anti-N kakaretso ea Ig Roche.Litlhahlobo ka bobeli li ile tsa lula li le hlokolosi ho feta likhoeli tse 8 kamora ts'oaetso.Kahoo, liphetho tsena li senotse hore li-immunoassays ka bobeli tsa Roche li loketse ho hakanya seroprevalence kamora nako e telele kamora ts'oaetso ea pele.

Ka mor'a moo, ba sebelisa litlhahlobo tsa ketsiso, bafuputsi ba ile ba etsa qeto ea hore ntle le mokhoa o nepahetseng oa quantification, haholo-holo, ho nahana ka kutloisiso ea nako e fapaneng ea tlhahlobo, lipatlisiso tsa seroprevalence li ke ke tsa nepahala.Sena se ka lebisa tlhokomelong e tlase ea palo ea 'nete ea ts'oaetso e ntseng e eketseha sechabeng.Boithuto bona ba immunoassay bo bonts'itse boteng ba liphapano tsa litekanyetso tsa seropositivity lipakeng tsa liteko tse fumanehang khoebong.

Ho lokela ho hlokomeloa hore ho na le mefokolo e mengata ea phuputso ena.Ka mohlala, reagent e sebelisitsoeng ha e ntse e etsa tlhahlobo ea EI bakeng sa bobeli ba motheo (teko ea pele kapa ea 1st) le ho latela (teko ea 2 bakeng sa bonkgetheng ba tšoanang) lisampole ka nako e itseng ea nako li ne li fapane.Khaello e 'ngoe ea phuputso ena ke hore lihlopha ha li kenyeletse bana.Ho fihlela joale, ha ho na bopaki ba hore nako e telele ea li-antibody dynamics ho bana e ngotsoe.


Nako ea poso: Mar-24-2021